We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. After previously discontinuing infliximab, 35% of ...

Please provide your email address to receive an email when new articles are posted on . Under Medicare Part D drug benefits, the biosimilar infliximab-dyyb was only 18% less expensive than the ...

Infliximab is a monoclonal antibody, prescribed for autoimmune disorders, joint pain, Crohn's disease, inflammatory bowel disease, ankylosing spondylitis, psoriasis. The risk or severity of adverse ...

Intensified or accelerated dosing regimens with infliximab (Remicade) did not improve outcomes compared with the standard regimen in patients with steroid-refractory acute severe ulcerative colitis ...

The study, with a small sample size, said most patients who take infliximab for more than 6 years report continued efficacy. Infliximab can be safe and effective as a long-term therapy in people with ...

Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Crohn's disease without fistulas. It is not known whether infliximab is an ...

ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

Infliximab is a medication used to reduce the symptoms and signs of several chronic inflammatory disorders. It is approved for the treatment of Crohn’s disease, rheumatoid arthritis, psoriasis, ...

Infliximab plus the other antitumor necrosis factor (anti-TNF) agents, adalimumab and certolizumab, are effective in patients with Crohn's disease who have inflammatory-type disease. By the time ...

A Pediatric Blood and Marrow Transplant Consortium (PBMTC) survey was undertaken in early 2002 to capture information about current clinical practice using infliximab in children with GVHD to plan a ...

An infliximab biosimilar (infliximab-axxq) delivered via subcutaneous injection was superior to intravenous vedolizumab (Entyvio) for induction and maintenance therapy of Crohn's disease (CD), ...